These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis. Zhu F; Jia S; Xing G; Gao L; Zhang L; He F DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166 [TBL] [Abstract][Full Text] [Related]
8. An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. Mazzieri R; D'Alessio S; Kenmoe RK; Ossowski L; Blasi F Mol Biol Cell; 2006 Jan; 17(1):367-78. PubMed ID: 16267271 [TBL] [Abstract][Full Text] [Related]
9. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. Busso N; Masur SK; Lazega D; Waxman S; Ossowski L J Cell Biol; 1994 Jul; 126(1):259-70. PubMed ID: 7517943 [TBL] [Abstract][Full Text] [Related]
11. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Stahl A; Mueller BM Cancer Res; 1994 Jun; 54(11):3066-71. PubMed ID: 8187097 [TBL] [Abstract][Full Text] [Related]
12. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor. Nagase K; Kobayashi H; Yoshikawa E; Kurita N J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319 [TBL] [Abstract][Full Text] [Related]
13. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction. Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694 [TBL] [Abstract][Full Text] [Related]
14. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression. Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810 [TBL] [Abstract][Full Text] [Related]
15. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401 [TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of a surface receptor bound urokinase-type plasminogen activator in a human metastatic carcinomatous cell line. Takahashi K; Kwaan HC; Ikeo K; Koh E Biochem Biophys Res Commun; 1992 Feb; 182(3):1466-72. PubMed ID: 1311574 [TBL] [Abstract][Full Text] [Related]
17. Regulated localization confers multiple functions on the protease urokinase plasminogen activator. Wells JM; Strickland S J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470 [TBL] [Abstract][Full Text] [Related]
18. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936 [TBL] [Abstract][Full Text] [Related]
19. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo. Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305 [TBL] [Abstract][Full Text] [Related]
20. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]